Search research articles
Contact Us
Filters
Showing results (111-120 of 129) with videos related to
Page
of 13
Sort By:
Journal of Medicinal Chemistry
|
April 21, 2017
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Mary E Matyskiela, Weihong Zhang, Hon-Wah Man, et al.
Leukemia
|
May 4, 2012
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A Lopez-Girona, D Mendy, T Ito, et al.
British Journal of Haematology
|
November 12, 2013
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
Anita K Gandhi, Derek Mendy, Michelle Waldman, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 6, 2011
Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors
Garrick K Packard, Patrick Papa, Jennifer R Riggs, et al.
Nature Structural & Molecular Biology
|
August 11, 2014
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Philip P Chamberlain, Antonia Lopez-Girona, Karen Miller, et al.
Nature
|
June 25, 2016
A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase
Mary E Matyskiela, Gang Lu, Takumi Ito, et al.
Nature
|
July 2, 2015
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Jan Krönke, Emma C Fink, Paul W Hollenbach, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|
July 29, 2025
Global Survey of Extracorporeal Membrane Oxygenation Transport Programs: Variability in Team Composition, Training, and Capabilities
Adam L Gottula, Lauren Gillespie, Michael Lauria, et al.
Journal of Medicinal Chemistry
|
March 5, 2020
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
Joshua D Hansen, Matthew Correa, Mark A Nagy, et al.
Molecular Cancer Therapeutics
|
April 10, 2015
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
Deborah S Mortensen, Kimberly E Fultz, Shuichan Xu, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 129) with videos related to
Sort By:
Page
of 13
Journal of Medicinal Chemistry
|
April 21, 2017
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Mary E Matyskiela, Weihong Zhang, Hon-Wah Man, et al.
Leukemia
|
May 4, 2012
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A Lopez-Girona, D Mendy, T Ito, et al.
British Journal of Haematology
|
November 12, 2013
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
Anita K Gandhi, Derek Mendy, Michelle Waldman, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 6, 2011
Discovery and optimization of thieno[2,3-d]pyrimidines as B-Raf inhibitors
Garrick K Packard, Patrick Papa, Jennifer R Riggs, et al.
Nature Structural & Molecular Biology
|
August 11, 2014
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Philip P Chamberlain, Antonia Lopez-Girona, Karen Miller, et al.
Nature
|
June 25, 2016
A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase
Mary E Matyskiela, Gang Lu, Takumi Ito, et al.
Nature
|
July 2, 2015
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Jan Krönke, Emma C Fink, Paul W Hollenbach, et al.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|
July 29, 2025
Global Survey of Extracorporeal Membrane Oxygenation Transport Programs: Variability in Team Composition, Training, and Capabilities
Adam L Gottula, Lauren Gillespie, Michael Lauria, et al.
Journal of Medicinal Chemistry
|
March 5, 2020
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma
Joshua D Hansen, Matthew Correa, Mark A Nagy, et al.
Molecular Cancer Therapeutics
|
April 10, 2015
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization
Deborah S Mortensen, Kimberly E Fultz, Shuichan Xu, et al.
Page
of 13